Aisling plots a new $500M biotech fund

Aisling Capital is raising a new fund, looking to gather up to $500 million for a new wave of life science investments, according to a report in Fortune. Aisling's last fund rang in at $650 million, but the scoop from Dan Primack says this new effort is aimed at rounding up $400 million with a hard cap at $500 million. Aisling's recent biotech investments include a stake in an $80 million round for Allergen Research and a $53 million raise for Watertown, MA-based Syros. Story

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.